# Molecular Cancer Therapeutics

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/molecular-cancer-therapeutics/

## Facts

| Field | Value |
| --- | --- |
| Citations | 372,106 |
| h-index | 218 |
| Homepage | http://mct.aacrjournals.org |
| Open Access | false |
| ISSN-L | 1535-7163 |
| ISSNs | 1535-7163,1538-8514 |
| OpenAlex ID | https://openalex.org/S48437117 |
| Publisher | American Association for Cancer Research |
| Works | 12,741 |

## Journal papers

Showing 12 of 28.

- [Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers](https://scholariq.org/papers/tumor-mutational-burden-as-an-independent-predictor-of-response-to-immunotherapy/)
- [PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy](https://scholariq.org/papers/pd-l1-expression-as-a-predictive-biomarker-in-cancer-immunotherapy/)
- [Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib](https://scholariq.org/papers/stereospecific-parp-trapping-by-bmn-673-and-comparison-with-olaparib-and/)
- [Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial](https://scholariq.org/papers/preclinical-selection-of-a-novel-poly-adp-ribose-polymerase-inhibitor-for/)
- [Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma](https://scholariq.org/papers/inhibition-of-akt-reverses-the-acquired-resistance-to-sorafenib-by-switching/)
- [Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments](https://scholariq.org/papers/tumor-cells-chronically-treated-with-a-trastuzumab-maytansinoid-antibody-drug/)
- [CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment](https://scholariq.org/papers/csf1-csf1r-signaling-inhibitor-pexidartinib-plx3397-reprograms-tumor-associated/)
- [Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2](https://scholariq.org/papers/mechanism-of-action-of-isothiocyanates-the-induction-of-are-regulated-genes-is/)
- [1α,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells](https://scholariq.org/papers/1-25-dihydroxyvitamin-d3-calcitriol-inhibits-hypoxia-inducible-factor-1-vascular/)
- [Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities](https://scholariq.org/papers/genome-and-transcriptome-sequencing-in-prospective-metastatic-triple-negative/)
- [Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor](https://scholariq.org/papers/antitumor-activity-and-pharmacokinetic-properties-of-pf-00299804-a-second/)
- [Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)](https://scholariq.org/papers/caveolae-mediated-endocytosis-as-a-novel-mechanism-of-resistance-to-trastuzumab/)

## Journal top topics

Showing 8 of 25.

- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)
- [Cancer-related Molecular Pathways](https://scholariq.org/topics/cancer-related-molecular-pathways/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Research and Treatments](https://scholariq.org/topics/cancer-research-and-treatments/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.